AAAAAA
Results: 1-25/27
Authors:
LINDBLAD R
RODJER S
ADRIANSSON M
ANDREASSON B
BACKSTOM B
JOHANSSON P
KARLSSON K
RHEDIN C
TURESSON I
Citation: R. Lindblad et al., EMPIRIC MONOTHERAPY FOR FEBRILE NEUTROPENIA - A RANDOMIZED STUDY COMPARING MEROPENEM WITH CEFTAZIDIME, Scandinavian journal of infectious diseases, 30(3), 1998, pp. 237-243
Authors:
BURNET NG
JOHANSEN J
TURESSON I
NYMAN J
PEACOCK JH
Citation: Ng. Burnet et al., DESCRIBING PATIENTS NORMAL TISSUE-REACTIONS - CONCERNING THE POSSIBILITY OF INDIVIDUALIZING RADIOTHERAPY DOSE PRESCRIPTIONS BASED ON POTENTIAL PREDICTIVE ASSAYS OF NORMAL TISSUE RADIOSENSITIVITY, International journal of cancer, 79(6), 1998, pp. 606-613
Authors:
HJORTH M
HOMBERG E
RODJER S
TURESSON I
WESTIN J
WISLOFF F
Citation: M. Hjorth et al., SURVIVAL IN CONVENTIONALLY TREATED YOUNGER (LESS-THAN-60 YEARS) MULTIPLE-MYELOMA PATIENTS - NO PROGRESS DURING 2 DECADES, British Journal of Haematology, 102(1), 1998, pp. 354-355
Authors:
BRINCKER H
WESTIN J
ABILDGAARD N
GIMSING P
TURESSON I
HEDENUS M
FORD J
KANDRA A
Citation: H. Brincker et al., FAILURE OF ORAL PAMIDRONATE TO REDUCE SKELETAL MORBIDITY IN MULTIPLE-MYELOMA - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL, British Journal of Haematology, 101(2), 1998, pp. 280-286
Authors:
SEIDEL C
BORSET M
TURESSON I
ABILDGAARD N
SUNDAN A
WAAGE A
Citation: C. Seidel et al., ELEVATED SERUM CONCENTRATIONS OF HEPATOCYTE GROWTH-FACTOR IN PATIENTSWITH MULTIPLE-MYELOMA, Blood, 91(3), 1998, pp. 806-812
Authors:
BURNET NG
JOHANSEN J
TURESSON I
NYMAN J
PEACOCK JH
Citation: Ng. Burnet et al., DESCRIBING PATIENTS NORMAL TISSUE-REACTIONS - A NECESSITY FOR DEVELOPMENT OF PREDICTIVE TESTING OF NORMAL TISSUE RADIOSENSITIVITY, European journal of cancer, 33, 1997, pp. 88-88
Authors:
SAETER G
ALVEGARD TA
MONGE OR
STRANDER H
TURESSON I
KLEPP R
SODERBERG M
WIST E
RAABE N
ERLANSON M
SOLHEIM OP
HANNISDAL E
Citation: G. Saeter et al., IFOSFAMIDE AND CONTINUOUS-INFUSION ETOPOSIDE IN ADVANCED ADULT SOFT-TISSUE SARCOMA - A SCANDINAVIAN SARCOMA GROUP PHASE-II STUDY, European journal of cancer, 33(10), 1997, pp. 1551-1558
Authors:
AALTONEN P
BRAHME A
LAX I
LEVERNES S
NASLUND I
REITAN JB
TURESSON I
Citation: P. Aaltonen et al., SPECIFICATION OF DOSE DELIVERY IN RADIATION-THERAPY - RECOMMENDATIONSBY THE NORDIC-ASSOCIATION-OF-CLINICAL-PHYSICS (NACP), Acta oncologica, 36, 1997, pp. 1-32
Authors:
SEIDEL C
BORSET H
TURESSON I
ABILDGAARD N
SUNDAN A
WAAGE A
Citation: C. Seidel et al., PROGNOSTIC INFORMATION OF HEPATOCYTE GROWTH-FACTOR IN SERUM OF MYELOMA PATIENTS, Blood, 90(10), 1997, pp. 1563-1563
Authors:
SIMONSSON B
OBERG G
LINDER O
BJORKHOLM M
CARNESKOG J
STENKE L
KARLE H
LANNGNIELSEN J
LOFVENBERG E
MALM C
PAUL C
TURESSON I
UDEN AM
VILEN L
WEISBJERRUM O
Citation: B. Simonsson et al., INTENSIVE TREATMENT IN ORDER TO MINIMIZE THE PH-POSITIVE CLONE IN CML, Blood, 90(10), 1997, pp. 1744-1744
Authors:
MERLINI G
TURESSON I
Citation: G. Merlini et I. Turesson, UTILITY OF BISPHOSPHONATES IN TREATING BONE METASTASES, Medical oncology, 13(4), 1996, pp. 215-221
Authors:
TURESSON I
NYMAN J
HOLMBERG E
ODEN A
Citation: I. Turesson et al., PROGNOSTIC FACTORS FOR ACUTE AND LATE SKIN REACTIONS IN RADIOTHERAPY PATIENTS, International journal of radiation oncology, biology, physics, 36(5), 1996, pp. 1065-1075
Authors:
SIMONSSON B
OBERG G
BJOREMAN M
BJORKHOLM M
CARNESKOG J
GAHRTON G
HAST R
KARL H
LANNGNIELSEN J
LOFVENBERG E
MALM C
TURESSON I
UDEN AM
VILEN L
WEISBJERRUM O
Citation: B. Simonsson et al., INTENSIVE TREATMENT IN ORDER TO MINIMIZE THE PH-POSITIVE CLONE IN CML, Bone marrow transplantation, 17, 1996, pp. 63-64
Authors:
TURESSON I
JOINER MC
Citation: I. Turesson et Mc. Joiner, CLINICAL-EVIDENCE OF HYPERSENSITIVITY TO LOW-DOSES IN RADIOTHERAPY, Radiotherapy and oncology, 40(1), 1996, pp. 1-3
Authors:
HJORTH M
WESTIN J
DAHL IMS
GIMSING P
HIPPE E
HOLMBERG E
LAMVIK J
NIELSEN JL
LOFVENBERG E
PALVA IP
RODJER S
TALSTAD I
TURESSON I
WISLOFF F
ZADOR G
AMSLERNORDIN S
POLGARY M
ODEN A
WALLGREN A
WILHELMSEN L
HELLQVIST L
HASSELBLOM S
CARNESKOG J
LINDQVIST O
HOFFMAN P
OLSSON K
THOLEN A
STOLT CM
RINDNER A
SVENSSON R
VAART J
HANSEN S
ENGQVIST L
LANNEMYR O
NILSSON PG
LINNE I
LILJA G
TALLROTH G
HALLGREN J
ANDERSSON B
BILLSTROM R
PERSSON S
SAMUELSSON T
ODEBERG H
ADRIANSSON M
TOVE H
STOBEUS N
HABBERSTAD J
END T
DAHLEN M
ERIKSSON M
ANAGRIUS N
ARONSON D
NEZADAL L
ERIKSSON K
HEDENUS M
RYDE J
WESTIN L
ANDERSSON LO
BJURMAN A
FORSBERG K
FORS D
WIKSTROM S
THULE B
BOLSOY U
LENNERMO K
STRAND T
PALVA I
ALMQVIST A
ISOMAA B
OKSANEN K
EIKA C
LY B
BRANDT E
WEYDE K
FOSSUM C
LOVASEN K
SPARBY JA
JACOBSEN EM
RINDE M
NYHUS S
KAHRS J
STEEN T
GRAVDAHL H
BORGE L
GROTTUM KA
FLOTTEROD O
STROM BR
KNUTSEN H
DRIVENES A
PAULSEN J
RIIS S
HAUGE PW
NESTHUS I
COLL P
HOLE KH
SAETER T
SINDRE T
BERENTSEN S
NES H
VAGSTAD G
HEIKKELA R
SHAMMAS V
LODEMEL B
SKOGEN OR
SORUM Y
KVAMBE V
BULL O
JAEGER S
INGVALDSEN PG
PEDERSEN K
HANSEN LT
ONKIEHONG M
HAUGNES T
STEFANSEN D
GADEBERG O
ABILDGAARD N
JANS H
MOURITSANDERSEN T
NEUBAUER B
CLAUSEN NT
MAGNUSSON S
EYJOLFSSON G
BJORNSSON S
Citation: M. Hjorth et al., INTERFERON-ALPHA-2B ADDED TO MELPHALAN-PREDNISONE FOR INITIAL AND MAINTENANCE THERAPY IN MULTIPLE-MYELOMA - A RANDOMIZED, CONTROLLED TRIAL, Annals of internal medicine, 124(2), 1996, pp. 212
Authors:
JOHANSSON B
ARHEDEN K
HOGLUND M
OTHZEN A
BEKASSY AN
TURESSON I
HEIM S
MITELMAN F
Citation: B. Johansson et al., FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS OF WHOLE-ARM 7-12-TRANSLOCATIONS IN HEMATOLOGIC MALIGNANCIES, Genes, chromosomes & cancer, 14(1), 1995, pp. 56-62
Authors:
BROCK WA
TUCKER SL
GEARA FB
TURESSON I
WIKE J
NYMAN J
PETERS LJ
Citation: Wa. Brock et al., FIBROBLAST RADIOSENSITIVITY VERSUS ACUTE AND LATE NORMAL SKIN-RESPONSES IN PATIENTS TREATED FOR BREAST-CANCER, International journal of radiation oncology, biology, physics, 32(5), 1995, pp. 1371-1379
Authors:
CRONQVIST AKA
KALLMAN P
TURESSON I
BRAHME A
Citation: Aka. Cronqvist et al., VOLUME AND HETEROGENEITY DEPENDENCE OF THE DOSE-RESPONSE RELATIONSHIPFOR HEAD AND NECK TUMORS, Acta oncologica, 34(6), 1995, pp. 851-860
Authors:
BURNET NG
NYMAN J
TURESSON I
WURM R
YARNOLD JR
STEEL GG
PEACOCK JH
Citation: Ng. Burnet et al., PREDICTION OF NORMAL TISSUE TOLERANCE FROM IN-VITRO CELLULAR RADIATION SENSITIVITY - RESPONSE, Radiotherapy and oncology, 36(3), 1995, pp. 245-246
Authors:
NYMAN J
TURESSON I
Citation: J. Nyman et I. Turesson, DOES THE INTERVAL BETWEEN FRACTIONS MATTER IN THE RANGE OF 4-8 H IN RADIOTHERAPY - A STUDY OF ACUTE AND LATE HUMAN SKIN REACTIONS, Radiotherapy and oncology, 34(3), 1995, pp. 171-178
Authors:
WESTIN J
RODJER S
TURESSON I
CORTELEZZI A
HJORTH M
ZADOR G
Citation: J. Westin et al., INTERFERON ALFA-2B VERSUS NO MAINTENANCE THERAPY DURING THE PLATEAU-PHASE IN MULTIPLE-MYELOMA - A RANDOMIZED STUDY, British Journal of Haematology, 89(3), 1995, pp. 561-568
Authors:
SIMONSSON B
OBERG G
KILLANDER A
BJOREMAN M
BJORKHOLM M
GAHRTON G
STENKE L
TURESSON I
UDEN AM
MALM C
VILEN L
WAHLIN A
LOFVENBERG E
CARNESKOG J
WESTIN J
Citation: B. Simonsson et al., INTENSIVE TREATMENT IN ORDER TO MINIMIZE THE PH-POSITIVE CLONE IN CHRONIC MYELOGENIC LEUKEMIA (CML), Bone marrow transplantation, 14, 1994, pp. 55-56
Authors:
BURNET NG
NYMAN J
TURESSON I
WURM R
YARNOLD JR
PEACOCK JH
Citation: Ng. Burnet et al., THE RELATIONSHIP BETWEEN CELLULAR RADIATION SENSITIVITY AND TISSUE-RESPONSE MAY PROVIDE THE BASIS FOR INDIVIDUALIZING RADIOTHERAPY SCHEDULES, Radiotherapy and oncology, 33(3), 1994, pp. 228-238
Authors:
NYMAN J
TURESSON I
Citation: J. Nyman et I. Turesson, BASAL-CELL DENSITY IN HUMAN SKIN FOR VARIOUS FRACTIONATION SCHEDULES IN RADIOTHERAPY, Radiotherapy and oncology, 33(2), 1994, pp. 117-124
Authors:
HELLSTROMLINDBERG E
CARLSSON M
CARNESKOG J
DAHL IM
DYBEDAL I
GRIMFORS G
LINDEMALM C
LINDER O
LOFVENBERG E
NILSSONEHLE H
TANGEN JM
TURESSON I
WINQVIST I
OBERG G
BEGIN Y
OST A
Citation: E. Hellstromlindberg et al., SYNERGISTIC EFFECT OF G-CSF AND EPO ON THE ANEMIA IN PATIENTS WITH MDS - EVIDENCE FOR INCREASED ERYTHROPOIETIC EFFECTIVENESS RATHER THAN EXPANSION, Blood, 84(10), 1994, pp. 10000317-10000317